The Oncology Institute recently achieved its first profitable Adj. EBITDA for the month and posted 37% YoY revenue growth, beating consensus by $13.9M. TOI raised FY25 guidance to $500M revenue and expects positive Adj. EBITDA in Q4, with cash flow positivity likely by mid-2026. Despite a massive share price surge in 12 months, GAAP EPS profitability remains two years away; consolidation is expected before a favorable entry point.
The Oncology Institute, Inc. ( TOI ) Q3 2025 Earnings Call November 13, 2025 5:00 PM EST Company Participants Mark Hueppelsheuser - General Counsel Daniel Virnich - CEO & Executive Director Rob Carter - Chief Financial Officer Conference Call Participants David Larsen - BTIG, LLC, Research Division Yuan Zhi - B. Riley Securities, Inc., Research Division Robert LeBoyer - NOBLE Capital Markets, Inc., Research Division Presentation Operator Greetings, and welcome to The Oncology Institute Third Quarter 2025 Earnings Call.
The Oncology Institute, Inc. (TOI) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.18 per share a year ago.
| Health Care Providers & Services Industry | Healthcare Sector | Daniel Virnich CEO | NASDAQ (CM) Exchange | 68236X100 CUSIP |
| US Country | 825 Employees | - Last Dividend | - Last Split | 15 Nov 2021 IPO Date |
The Oncology Institute, Inc. is an American oncology company specializing in a wide range of oncology services. Founded in 2007 and headquartered in Cerritos, California, the institute is dedicated to providing comprehensive care for adult and senior cancer patients. With 67 clinic locations across the United States, it offers a broad spectrum of integrated services aimed at the management and treatment of cancer. The company's approach to cancer care includes a combination of medical oncology services, innovative therapies, and patient support programs designed to address the individual needs of each patient.